Amer A. Beg

University Hospitals Birmingham NHS Foundation Trust — United Kingdom

Medicine · Health Sciences

53h-index19.4kcitations290works1.22yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer Immunotherapy and Biomarkers(74), NF-κB Signaling Pathways(55), Immunotherapy and Immune Responses(40), Immune Response and Inflammation(39), Immune Cell Function and Interaction(29)

Publications289 total

Distinct Tumor-Immune Ecologies in Lung Cancer PatientsPredict Progression and Define a Clinical Biomarker of Therapy Response
Cancer Research·2025
Sequestration of the phagocyte metabolite itaconate by Pseudomonas aeruginosa RpoN promotes successful pulmonary infection
Nature Communications·2025Open Access
16 A rare case of metastasis to the median lingual lymph node in squamous cell carcinoma of the tongue
British Journal of Oral and Maxillofacial Surgery·2025
Supplementary Table 2 from Combination IFNβ and Membrane-Stable CD40L Maximize Tumor Dendritic Cell Activation and Lymph Node Trafficking to Elicit Systemic T-cell Immunity
2025Open Access
Supplementary Figures from Combination IFNβ and Membrane-Stable CD40L Maximize Tumor Dendritic Cell Activation and Lymph Node Trafficking to Elicit Systemic T-cell Immunity
2025Open Access
Supplementary Table 1 from Combination IFNβ and Membrane-Stable CD40L Maximize Tumor Dendritic Cell Activation and Lymph Node Trafficking to Elicit Systemic T-cell Immunity
2025Open Access
Supplementary Table Legends from Combination IFNβ and Membrane-Stable CD40L Maximize Tumor Dendritic Cell Activation and Lymph Node Trafficking to Elicit Systemic T-cell Immunity
2025Open Access
Supplementary Table 3 from Combination IFNβ and Membrane-Stable CD40L Maximize Tumor Dendritic Cell Activation and Lymph Node Trafficking to Elicit Systemic T-cell Immunity
2025Open Access
Figure S5 from RNA Shielding of p65 Is Required to Potentiate Oncogenic Inflammation in <i>TET2</i>-Mutated Clonal Hematopoiesis
2025Open Access
Table S3 from RNA Shielding of p65 Is Required to Potentiate Oncogenic Inflammation in <i>TET2</i>-Mutated Clonal Hematopoiesis
2025Open Access
Figure S1 from RNA Shielding of p65 Is Required to Potentiate Oncogenic Inflammation in <i>TET2</i>-Mutated Clonal Hematopoiesis
2025Open Access
Figure S2 from RNA Shielding of p65 Is Required to Potentiate Oncogenic Inflammation in <i>TET2</i>-Mutated Clonal Hematopoiesis
2025Open Access
Figure S4 from RNA Shielding of p65 Is Required to Potentiate Oncogenic Inflammation in <i>TET2</i>-Mutated Clonal Hematopoiesis
2025Open Access
Table S6 from RNA Shielding of p65 Is Required to Potentiate Oncogenic Inflammation in <i>TET2</i>-Mutated Clonal Hematopoiesis
2025Open Access
Table S2 from RNA Shielding of p65 Is Required to Potentiate Oncogenic Inflammation in <i>TET2</i>-Mutated Clonal Hematopoiesis
2025Open Access
Figure S7 from RNA Shielding of p65 Is Required to Potentiate Oncogenic Inflammation in <i>TET2</i>-Mutated Clonal Hematopoiesis
2025Open Access
Figure S6 from RNA Shielding of p65 Is Required to Potentiate Oncogenic Inflammation in <i>TET2</i>-Mutated Clonal Hematopoiesis
2025Open Access
Table S4 from RNA Shielding of p65 Is Required to Potentiate Oncogenic Inflammation in <i>TET2</i>-Mutated Clonal Hematopoiesis
2025Open Access
Figure S3 from RNA Shielding of p65 Is Required to Potentiate Oncogenic Inflammation in <i>TET2</i>-Mutated Clonal Hematopoiesis
2025Open Access
Table S1 from RNA Shielding of p65 Is Required to Potentiate Oncogenic Inflammation in <i>TET2</i>-Mutated Clonal Hematopoiesis
2025Open Access
page 1 of 15Next →

Frequent Co-authors

Albert S. Baldwin(7), Eric B. Haura(7), Ye Zheng(6), Junmei Wang(6), David Baltimore(5), Siddharth Balachandran(5), Timothy S. Finco(4), Ming O. Li(4), F Ouaaz(4), Steven A. Eschrich(3), Zhihua Chen(3), Scott Antonia(3), Suresh H. Basagoudanavar(3), Emily Hopewell(3), Crystina C. Bronk(3), William C. Sha(2), Roderick T. Bronson(2), Sankar Ghosh(2), Pascale V. Nantermet(2), A S Baldwin(2)